Abortion’s Tricky Past
The recent ruling by the Supreme Court sent the country into a tailspin of outrage. However, the problem is not ...
Opioids in Good Faith
The Supreme Court clarified the matter of good faith in opioid cases. The ruling will improve the patient-physician relationship and ...
Addiction Isn’t a Metric
The ONDCP announced an initiative aimed at reducing overdose deaths. But by limiting all of addiction into a metric, we ...
A Price on Patient Values
Policy makers believe price transparency will help patients make cost-effective decisions. But patient decisions are made through trust, not cost-savings.
Price Transparency Fallacy
We think disclosing the costs of clinical care will reduce overall costs. In reality, price transparency will increase the cost ...
Novavax: What is the Point?
We have approved a fourth vaccine, with the goal of addressing vaccine hesitancy. But hesitancy is irrational and unlikely to ...
Learning Medical Uncertainty
We teach medicine through memory. But memorizing facts does little to address the uncertainty that comes out of making decisions ...
Healthcare’s Problem With Logic
Medicine has always relied on intuition, that prescient gut instinct. But intuition is outcomes focused. Instead, we need logic, which ...
Listening to Young People Reduces Pandemic Harms
A better understanding of the pandemic’s effects on young people is essential to developing policy responses that can address the ...
Monkeypox, COVID, and Racism
With viruses dominating headlines, it is no surprise that the latest Monkeypox outbreak garners headlines. But the way we cover ...
Origins of the Drug Resistant Pandemic
For most, prescribing antibiotics is a simple decision made reflexively. However, that decision, seemingly logical in the moment, becomes dangerous ...
A Game of Healthcare Law
In game theory, outcomes depend on the nature of the game and the payoffs. Healthcare is a game of incomplete ...
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more